Galectin Therapeutics and SBH Sciences have jointly established Galectin Sciences, LLC, a collaborative venture to research and develop small organic molecule inhibitors of galectin-3 for oral administration.   SBH Sciences recently identified several molecules with promising galectin-3 inhibitory activity in vitro. Galectins are markedly increased in a number of diseases, including scarring of organs and many cancers. Galectin Sciences will collaborate on further development of these organic mo...